Expert Interview
A Second Perspective: Discussing a4b7 integrin blocking in moderate to severe ulcerative colitis: Looking at 1st gen PTG-100 and MORF-057
Ticker(s): MORF, PTGX, TAKInstitution: NYU
- Assistant Professor of Medicine in the Division of Gastroenterology at NYU Grossman School of Medicine & gastroenterologist at the IBD Center at NYU Langone Health.
- Principal investigator of the institutional NYU IBD biorepository, IBD and Clostridioides difficile clinical trials; manages ~500 patients with ulcerative colitis (150 moderate-severe).
- Research focuses on IBD epidemiology, pathogenic triggers of IBD onset and flare, and ex vivo models for predicting responsiveness to IBD therapies.
Roughly how many patients with UC do you currently manage?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for PTG-100? For MORF-057?
Added By: c_adminIf a patient doesn't respond to a4b7 inhibitor, what could be the reason?
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
